deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT02871479

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis

A Double-Blind, Randomized, Placebo-Controlled, Safety, Tolerability, and Efficacy Trial of a Novel Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For The Treatment of Atopic Dermatitis

Sponsor: ClinDatrix, Inc.

Conditions Atopic Dermatitis Eczema
Interventions Placebo SAN007 10% cream SAN007 5% cream
Updated 17 times since 2017 Last updated: May 6, 2019 Started: Apr 21, 2017 Primary completion: Aug 31, 2018 Completion: Aug 31, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02871479, this PHASE2 trial focuses on Atopic Dermatitis and Eczema and remains completed. Sponsored by ClinDatrix, Inc., it has been updated 17 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Nov 2017 · 3 months · monthly snapshot~Nov 2017 – ~Feb 2018 · 3 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Jan 2019 · 3 months · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Jun 2019 · 4 months · monthly snapshot~Jun 2019 – ~Jan 2021 · 19 months · monthly snapshot~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

  5. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE2

▶ Show 12 earlier versions

  1. Jun 2019 — Jan 2021 [monthly]

    Completed PHASE2

  2. Feb 2019 — Jun 2019 [monthly]

    Completed PHASE2

  3. Jan 2019 — Feb 2019 [monthly]

    Completed PHASE2

  4. Oct 2018 — Jan 2019 [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

  5. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  6. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  7. Nov 2017 — Feb 2018 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  8. Aug 2017 — Nov 2017 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  9. Jun 2017 — Aug 2017 [monthly]

    Recruiting PHASE2

  10. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  11. Feb 2017 — May 2017 [monthly]

    Not Yet Recruiting PHASE2

  12. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ClinDatrix, Inc.
  • Clinical Trials of Texas, Inc.
  • Derm Research, PLLC
  • Progressive Clinical Research
  • Santalis Pharmaceuticals, Inc.
  • Texas Dermatology and Laser Specialists
  • U.S. Dermatology Partners Bryan
Data source: Santalis Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations